Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone49-62-2165-3070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.03 million
Profitability
Miscellaneous
Employees8,406
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Affimed (NASDAQ:AFMD) Frequently Asked Questions
What is Affimed's stock symbol?
Affimed trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed's earnings last quarter?
Affimed NV (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, May, 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.19. The biopharmaceutical company had revenue of $12.89 million for the quarter, compared to analyst estimates of $6.77 million. Affimed had a negative net margin of 87.00% and a negative return on equity of 44.56%. View Affimed's Earnings History.
When is Affimed's next earnings date?
What price target have analysts set for AFMD?
5 analysts have issued 12 month price objectives for Affimed's shares. Their predictions range from $4.00 to $8.00. On average, they expect Affimed's stock price to reach $5.2340 in the next year. This suggests a possible upside of 68.8% from the stock's current price. View Analyst Price Targets for Affimed.
What is the consensus analysts' recommendation for Affimed?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.
Has Affimed been receiving favorable news coverage?
News headlines about AFMD stock have trended positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Are investors shorting Affimed?
Affimed saw a increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,030,187 shares, an increase of 97.9% from the March 29th total of 2,036,606 shares. Based on an average trading volume of 1,541,518 shares, the short-interest ratio is presently 2.6 days. Currently, 7.9% of the shares of the company are sold short. View Affimed's Current Options Chain.
Who are some of Affimed's key competitors?
Some companies that are related to Affimed include CannTrust (CNTTF), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Intra-Cellular Therapies (ITCI), Principia Biopharma (PRNB), Cara Therapeutics (CARA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), ChemoCentryx (CCXI), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), Kura Oncology (KURA) and Stemline Therapeutics (STML).
What other stocks do shareholders of Affimed own?
Who are Affimed's key executives?
Affimed's management team includes the folowing people:
- Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 57)
- Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 51)
- Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 55)
- Prof. Melvyn Little, Founder & Consultant
- Dr. Martin Treder, Chief Scientific Officer (Age 49)
Who are Affimed's major shareholders?
Affimed's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.58%), Bain Capital Public Equity Management LLC (2.41%), New Leaf Venture Partners L.L.C. (1.17%), Dimensional Fund Advisors LP (0.50%), Sio Capital Management LLC (0.43%) and Oxford Asset Management LLP (0.25%).
Which major investors are selling Affimed stock?
AFMD stock was sold by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Bain Capital Public Equity Management LLC and Dimensional Fund Advisors LP.
Which major investors are buying Affimed stock?
AFMD stock was purchased by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, BlueCrest Capital Management Ltd, Acadian Asset Management LLC, Oxford Asset Management LLP, Renaissance Technologies LLC, Wellington Management Group LLP, MYDA Advisors LLC and Jane Street Group LLC.
How do I buy shares of Affimed?
Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed's stock price today?
One share of AFMD stock can currently be purchased for approximately $3.10.
How big of a company is Affimed?
Affimed has a market capitalization of $193.41 million and generates $28.03 million in revenue each year. The biopharmaceutical company earns $-23,000,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. Affimed employs 8,406 workers across the globe.
What is Affimed's official website?
How can I contact Affimed?
Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]
MarketBeat Community Rating for Affimed (NASDAQ AFMD)
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
